ADPKD Water Intake Calculator
Estimate an osmolality-based water intake from measured 24-hour urine volume and urine osmolality.
Water Intake in ADPKD
Arginine vasopressin promotes cyst growth in autosomal dominant polycystic kidney disease (ADPKD), providing a biological rationale for maintaining adequate hydration and avoiding dehydration.
KDIGO 2025 suggests adapting water intake, spread throughout the day, to achieve at least 2–3 liters of water intake per day in people with ADPKD who have an eGFR ≥30 mL/min/1.73 m² and no contraindications to excreting a solute load. This recommendation applies to water intake in the absence of tolvaptan and should be individualized.
However, evidence that prescribed high water intake slows ADPKD progression remains limited. In the 3-year PREVENT-ADPKD randomized trial, prescribed water intake reduced urine osmolality but did not significantly slow total kidney-volume growth or kidney-function decline compared with usual water intake.
Calculate an Osmolality-Based Water Estimate
This calculator estimates the daily water intake used in a published ADPKD low-osmolar-diet and adjusted-water protocol targeting a mean urine osmolality of approximately 280 mOsm/kg.
Enter values from a complete 24-hour urine collection.
Calculate an Osmolality-Based Water Estimate
Enter measured 24-hour urine volume and 24-hour urine osmolality.
Estimated Daily Water Intake
liters/day
Estimated 24-hour urinary solute: mOsm/day
Urine osmolality target: approximately 280 mOsm/kg H₂O
Estimated insensible water loss: 0.5 L/day
This is a physiologic estimate based on a published osmolality-targeted water-intake method. It is not a validated treatment target proven to slow ADPKD progression. Individual fluid recommendations should account for kidney function, medications, sodium balance, comorbidities, and the patient's ability to safely excrete a water load.
How the Estimate Is Calculated
The calculation is based on measured 24-hour urine volume and urine osmolality.
Estimated daily urinary solute excretion = 24-hour urine volume × urine osmolality
Estimated water intake = daily urinary solute excretion ÷ 280 + 0.5 L
The additional 0.5 L accounts for estimated insensible water losses.
This calculation reproduces an osmolality-based water-prescription method studied in ADPKD. It should not be interpreted as proof that achieving this calculated intake slows progression of ADPKD.
Before Recommending Increased Water Intake
Increased water intake is not appropriate for everyone with ADPKD. Clinical circumstances that may require caution or individualized fluid advice include:
• Baseline hyponatremia
• Heart failure, cirrhosis, or other conditions associated with risk of fluid overload
• A clinical requirement for fluid restriction
• Medications that may increase the risk of hyponatremia
• eGFR below 30 mL/min/1.73 m²
Tolvaptan requires a different approach to water intake because it causes aquaresis. People taking tolvaptan should be counseled to respond to thirst and drink enough water to replace urinary water losses rather than use this calculator as a treatment prescription.
What the Evidence Shows
Biological Rationale
Vasopressin promotes cystogenesis in ADPKD. Increasing water intake can suppress vasopressin activity and lower urine osmolality.
Physiological Effect
Prescribed water intake can increase urine volume and lower urine osmolality, although maintaining a low urine-osmolality target over time can be difficult.
Clinical Outcomes
Prescribed high water intake has not been shown to slow ADPKD progression. PREVENT-ADPKD found no significant reduction in kidney-volume growth or eGFR decline over 3 years.
Clinical-Use Notice
This calculator provides an estimate derived from a published research protocol. It is not a validated treatment prescription and does not establish that the calculated water intake will slow ADPKD progression.
Fluid recommendations should be individualized according to kidney function, serum sodium, medications, cardiovascular and liver status, use of tolvaptan, dietary solute intake, and other relevant clinical factors.